For instance, the recent widespread use of novel cancer therapies with potential cardiovascular consequences, such as tyrosine kinase inhibitors in chronic myeloid leukaemia,10 trastuzumab in breast cancer,11 proteasome inhibitors in multiple myeloma,12 and vascular endothelial growth factor (VEGF) signalling pathway inhibitors for treatment of gastrointestinal and genitourinary cancers,13 is expected to impact CVD patterns in cancer patients. This evidence concerns the gene VEGFA and chronic myelogenous leukemia, BCR-ABL1 positive.